Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15464597 | 0.92 | ALDH1A1 (0.36) | AHRALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12016624 | 0.92 | ALDH1A1 (0.36) | AHRALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12467754 | 0.92 | ALDH1A1 (0.36) | AHRALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15465728 | 0.92 | ALDH1A1 (0.36) | AHRALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2899421 | 0.90 | AHR (0.40) | THRBAHRCYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL16214294 | 0.88 | ABCB11 (0.35) | AHRALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL19240712 | 0.88 | ABCB11 (0.35) | AHRALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12016623 | 0.87 | ALDH1A1 (0.39) | AHRALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15583426 | 0.86 | TBXAS1 (0.34) | AHRALDH1A1TBXAS1CYP24A1TDP1 | |
| SCHEMBL12468229 | 0.84 | TDP1 (0.32) | AHRALDH1A1TBXAS1CYP24A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110165037-A1 | INTERFACES THAT ELIMINATE NON-SPECIFIC ADSORPTION, AND INTRODUCE SPECIFIC INTERACTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165037-A1 | INTERFACES THAT ELIMINATE NON-SPECIFIC ADSORPTION, AND INTRODUCE SPECIFIC INTERACTIONS | EPCAM, SLCO2B1, SLCO4C1 | THRB 1464/4885AHR 2269/4885CYP19A1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.